Major haemorrhagic complications during oral anticoagulant therapy in a Danish population-based cohort

被引:87
作者
Steffensen, FH
Kristensen, K
Ejlersen, E
Dahlerup, JF
Sorensen, HT
机构
[1] Univ Aarhus, Danish Epidemiol Sci Ctr, DK-8000 Aarhus C, Denmark
[2] Aarhus Univ Hosp, Dept Med C, DK-8000 Aarhus, Denmark
[3] Aarhus Univ Hosp, Dept Med 5, DK-8000 Aarhus, Denmark
[4] Aalborg Hosp, Dept Med M, Aalborg, Denmark
关键词
anticoagulant therapy; haemorrhage;
D O I
10.1111/j.1365-2796.1997.tb00023.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives, To estimate the incidence of bleeding leading to death or hospital admission in out-patients treated with oral anticoagulants. Design, Population-based historical cohort study 1 January 1992 to 31 September 1994. Setting, The County of North Jutland, Denmark (488 000 inhabitants). Subjects, Six hundred and eighty-two consecutive patients commencing oral anticoagulant therapy. Main outcome measures. Fatal bleeding or bleeding demanding hospital admission. Results. In 756 treatment-years of follow-up, there were 45 major haemorrhagic events (6.0 per 100 treatment-years) in 42 patients, of which seven (0.9 per 100 treatment-years) were fatal. The risk of a first major haemorrhagic episode was highest during the first 90 days of treatment compared with duration above one year (incidence rate ratio, IRR, 1.9; 95% CI, 0.8-4.1). The rate was highest above the age of 60 years, 6.8 per 100 treatment-years, compared with 2.9 per 100 treatment-years below 60 years (IRR 2.3; 95% CI, 1.0-5.6). The rate for a bleeding event was slightly higher in females than in males (IRR 1.3; 95% CI, 0.7-2.3), but did not vary according to type of anticoagulant drug. Conclusions. The reported rates of major bleeding in this routine community setting implied a higher bleeding risk than was found in randomized trials or when patients are monitored in specialist anticoagulation clinics.
引用
收藏
页码:497 / 503
页数:7
相关论文
共 23 条
  • [1] [Anonymous], 1994, Lancet, V343, P499
  • [2] Clayton D., 1993, STAT MODELS EPIDEMIO
  • [3] *EAFT, 1992, LANCET, V342, P1255
  • [4] RISK-FACTORS FOR COMPLICATIONS OF CHRONIC ANTICOAGULATION - A MULTICENTER STUDY
    FIHN, SD
    MCDONELL, M
    MARTIN, D
    HENIKOFF, J
    VERMES, D
    KENT, D
    WHITE, RH
    [J]. ANNALS OF INTERNAL MEDICINE, 1993, 118 (07) : 511 - 520
  • [5] ANTICOAGULATION IN ATRIAL-FIBRILLATION - DOES EFFICACY IN CLINICAL-TRIALS TRANSLATE INTO EFFECTIVENESS IN PRACTICE
    GOTTLIEB, LK
    SALEMSCHATZ, S
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1994, 154 (17) : 1945 - 1953
  • [6] COST-EFFECTIVENESS OF PRIMARY STROKE PREVENTION IN ATRIAL-FIBRILLATION - SWEDISH NATIONAL PERSPECTIVE
    GUSTAFSSON, C
    ASPLUND, K
    BRITTON, M
    NORRVING, B
    OLSSON, B
    MARKE, LA
    [J]. BRITISH MEDICAL JOURNAL, 1992, 305 (6867) : 1457 - 1460
  • [7] LANDEFELD CS, 1989, AM J MED, V87, P144
  • [8] ANTICOAGULANT-RELATED BLEEDING - CLINICAL EPIDEMIOLOGY, PREDICTION, AND PREVENTION
    LANDEFELD, CS
    BEYTH, RJ
    [J]. AMERICAN JOURNAL OF MEDICINE, 1993, 95 (03) : 315 - 328
  • [9] BLEEDING COMPLICATIONS TO ORAL ANTICOAGULANT-THERAPY - MULTIVARIATE-ANALYSIS OF 1010 TREATMENT YEARS IN 551 OUTPATIENTS
    LAUNBJERG, J
    EGEBLAD, H
    HEAF, J
    NIELSEN, NH
    FUGLEHOLM, AM
    LADEFOGED, K
    [J]. JOURNAL OF INTERNAL MEDICINE, 1991, 229 (04) : 351 - 355
  • [10] LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449